Gyre Therapeutics, Inc. Increase (Decrease) in Due to Related Parties
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Due to Related Parties of $4.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2026-08-07
- Gyre Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2024-12-31 was -$1.00K.
- Gyre Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2024-09-30 was -$196.00K, a 6633.33% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2024-06-30 was $120.00K, a 77.23% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in due to related parties for the quarter ending 2024-03-31 was -$6.00K.
- Gyre Therapeutics, Inc. increase (decrease) in due to related parties for fiscal 2025 was -$1.00K.
- Gyre Therapeutics, Inc. increase (decrease) in due to related parties for fiscal 2024 was -$83.00K, a 119.53% decline from fiscal 2023.
- Gyre Therapeutics, Inc. increase (decrease) in due to related parties for fiscal 2023 was $425.00K.
| Period end | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.80M 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | -$1.00K 10-K · filed 2026-03-13 | |||
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$197.00K derived: sum of 2 quarters · filed 2026-03-13 | -$77.00K derived: sum of 3 quarters · filed 2026-03-13 | -$83.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$76.00K derived: sum of 2 quarters · filed 2024-11-13 | -$82.00K 10-Q · filed 2024-11-13 | -$186.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2024-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $114.00K 10-Q · filed 2024-08-13 | $10.00K derived: sum of 3 quarters · filed 2025-03-17 | $13.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2024-03-31 | -$6.00K 10-Q · filed 2024-05-13 | -$110.00K derived: sum of 2 quarters · filed 2025-03-17 | -$107.00K derived: sum of 3 quarters · filed 2025-03-17 | $420.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-12-31 | -$104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$101.00K derived: sum of 2 quarters · filed 2025-03-17 | $426.00K derived: sum of 3 quarters · filed 2025-03-17 | $425.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $530.00K derived: sum of 2 quarters · filed 2024-11-13 | $529.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $527.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $526.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$1.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |